As this unforgettable year nears its close, we have upbeat news to report in this issue from the health care and oceans sectors.
Despite the COVID-19 pandemic, Genome Atlantic has never been busier. Our current portfolio has 23 active, funded projects worth nearly $50 million, encompassing 25 companies and 15 university partners.
These projects span all four Atlantic provinces and represent a broad range of sectors including human health, oceans (aquaculture and energy), environment, agriculture, forestry and mining.
Significantly, our portfolio includes an ever-increasing amount of private sector investment, which has grown from eight per cent in 2008 to between 20-30% in recent years.
As we track the beneficial, unfolding effects of the projects on our list, we continue to pilot new opportunities through our business development pipeline.
Based on our activity, genomics is poised to be a driving force in our region’s economic recovery.
At this time, we want to acknowledge the tremendous support of our many partners in government, academia, and industry throughout this unprecedented period. They have been a pleasure to work with.
To you, our subscribers, we extend our seasonal best wishes and the hope that you’ll find inspiration for the year ahead in the people and applied genomics projects highlighted in this issue.
We all know recovery won’t be instant or easy, and that it will be more important than ever for Atlantic Canada to back innovations with a proven track record of impact. Genomics is one of these technologies, delivering impressive ROI across a range of sectors strategic to Atlantic Canada’s health and prosperity and attracting high levels of private sector investment.
Our sleeves are rolled up and the path to our region’s greater prosperity lies ahead.